图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
免疫病理疾病及治疗学论文学
SJR: 0.309 SNIP: 0.041 CiteScore™: 0.18

ISSN 打印: 2151-8017
ISSN 在线: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

免疫病理疾病及治疗学论文学

DOI: 10.1615/ForumImmunDisTher.2015014027
pages 101-114

Alternative Scaffolds as Therapeutics in Cancer and Other Diseases

Ulrich Wuellner
Covagen AG, a Janssen Pharmaceutical Companies of Johnson & Johnson, CH-8952 Zurich-Schlieren, Switzerland
Dragan Grabulovski
Covagen AG, a Janssen Pharmaceutical Companies of Johnson & Johnson, CH-8952 Zurich-Schlieren, Switzerland

ABSTRACT

Alternative scaffold proteins are a growing class of engineered binding proteins that can be identified using modern protein-engineering technologies. From large combinatorial libraries, high-quality binders can be generated essentially against any target protein of interest. Typically, these binding proteins have favorable properties in terms of size, stability, or ease of production. In this review, we focus on alternative scaffold binders for applications mainly in oncology. We highlight recent advances in the field and provide a perspective on the potentials and challenges in the drug development process of these molecules.